Smart jab can shrink head and neck cancer tumours within six weeks, trial finds
a day ago
- #immunotherapy
- #medical innovation
- #cancer research
- Amivantamab, a triple-action smart jab, shows promise in shrinking tumors in head and neck cancer patients within six weeks.
- Head and neck cancer is the sixth most common cancer globally, with limited treatment options if immunotherapy and chemotherapy fail.
- The drug targets EGFR and MET pathways while boosting the immune system, offering a new approach to treatment.
- Administered as a simple injection, amivantamab is faster and more convenient than traditional therapies, potentially usable in outpatient clinics or at home.
- Early trial results show 76% of patients experienced tumor shrinkage or halted growth, with an average progression-free survival of 6.8 months.
- Side effects were mostly mild to moderate, and the treatment was well-tolerated by patients.
- Patient testimonials, like Carl Walsh's, highlight significant improvements in symptoms and quality of life.